Location Directory

Clinical trials in New Haven, Connecticut

This page shows live ClinicalTrials.gov search results for New Haven, Connecticut, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1352

Shown on this page

Current sort

Institutions in New Haven

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Yale

Live official records

Open in full search

Conditions: Aortic Stenosis
Interventions: Transthoracic echocardiogram; Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 65 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: New Haven, Connecticut • New York, New York • Houston, Texas

Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Interventions: Apixaban, Aspirin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 186
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 141 more

Conditions: Alopecia Areata
Interventions: bempikibart (ADX-914); Drug
Lead sponsor: Q32 Bio Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 28
States / cities: Scottsdale, Arizona • Fayetteville, Arkansas • Hot Springs, Arkansas + 24 more

Conditions: Alcohol Use Disorder, Alcohol-associated Liver Disease
Interventions: Implementation Intervention; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Aortic Stenosis, Mitral Stenosis, Aortic Valve Insufficiency, Mitral Valve Insufficiency, Heart Failure
Interventions: Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 777 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more

Conditions: Advanced Solid Tumors
Interventions: ABBV-706, Cisplatin, Budigalimab, Carboplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: Gilbert, Arizona • Duarte, California • Irvine, California + 18 more

Conditions: AL Amyloidosis
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Cyclophosphamide, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Echocardiography, Magnetic Resonance Imaging, Melphalan, Positron Emission Tomography, Stem Cell Isolation, Survey Administration; Procedure · Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 117
States / cities: Goodyear, Arizona • Tucson, Arizona • Duarte, California + 93 more

Conditions: Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel; Drug · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 782 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1286
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 815 more

Conditions: Severe Aortic Stenosis
Interventions: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: Not listed
Enrollment: 782 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 43
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 33 more

Conditions: Endometrial Neoplasms
Interventions: pembrolizumab, carboplatin, paclitaxel, docetaxel, cisplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 35
States / cities: Phoenix, Arizona • La Jolla, California • Riverside, California + 28 more

Conditions: Healthy Volunteer
Interventions: Test formulation (Treatment A), Reference formulation (Treatment B), Test formulation (Treatment C), Test formulation (Treatment D); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Respiratory Insufficiency, Respiratory Distress Syndrome, Newborn, Lung Diseases
Interventions: Team approach to sedation management, Usual approach to sedation management; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 2 Weeks to 18 Years
Enrollment: 2,449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 31
States / cities: Birmingham, Alabama • Tucson, Arizona • Oakland, California + 26 more

Clinical trials in New Haven, Connecticut

Filter and sort this location

Institutions in New Haven

Live official records

Deep Learning-enhanced Personalized Monitoring of Aortic Stenosis - The DETECT-AS Prognostic Study

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)

ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults

Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)